M
ultiple sclerosis (MS) is an autoimmune disease whose infl ammatory process causes demyelination, axonal loss, and neurodegeneration, all of which can lead to progressive neurologic disability. Without treatment, the risk of progressive disability 15 to 20 years after the onset of MS has been estimated to be as high as 50%. 1 Seven drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of MS. Of these, interferon beta drugs and glatiramer acetate are generally considered as fi rst-line agents based on extensive experience and relative safety. Indeed, reports with followup approaching 20 years have not identifi ed signifi cant safety concerns. However, these agents have only modest effi cacy, reducing by approximately 30% the frequency of relapse in patients with relapsing-remitting MS. [2] [3] [4] [5] [6] Natalizumab, and more recently, fi ngolimod, are generally used as second-line agents. Fingolimod, the fi rst oral agent to receive FDA approval for the treatment of relapsing-remitting MS, is a functional antagonist of sphingosine-1-phosphate receptors. The reductions in annualized relapse rates in two phase 3 controlled trials of fi ngolimod were approximately 55% compared with placebo 7 or intramuscular interferon beta-1a. 8 Because of its more convenient oral route of administration and its documented effi cacy, widespread use of fi ngolimod is anticipated. However, adverse reactions affecting more than 10% of patients include headache, infl uenza, diarrhea, back pain, liver transaminase elevations, and cough. 9 Because sphingosine-1-phosphate receptors are widespread in many body tissues, off-target effects of fi ngolimod may be problematic and long-term toxicity is unknown.
In addition to natalizumab and fi ngolimod, which are currently available for use as second-line agents, several other MS therapies are showing promise. Oral cladribine, terifl unomide, and laquinimod have reported positive phase 3 results in publication or at national meetings, and several other drugs are in late stages of development (alemtuzumab, BG-12, ocrelizumab) based on encouraging phase 2 results. [10] [11] [12] Thus, the options for MS patients are expanding, but drugs with higher effi cacy also may pose greater risk.
   NATALIZUMAB: ROBUST BENEFITS
BUT ASSOCIATED RISK Natalizumab is a humanized monoclonal antibody that binds to alpha-4 integrin on leukocytes. By inhibiting alpha-4 integrin, natalizumab, the fi rst of a new class of selective adhesion-molecule inhibitors, impedes migration of activated mononuclear leukocytes into the brain and gut. 13 
Signifi cant effi cacy
Two phase 3 studies demonstrated more robust effi cacy of natalizumab in patients with relapsing-remitting MS than had been observed in prior studies with other agents. 14, 15 In the Natalizumab Safety and Effi cacy in RelapsingRemitting Multiple Sclerosis (AFFIRM) study, which followed patients over 2 years of treatment, natalizumab was ; and an 83% reduction in the mean number of new or enlarging T2 lesions 16 compared with placebo. The likelihood of confi rmed worsening on the Kurtzke Expanded Disability Status Score, which is the standard measure for MS-related disability, was also 42% lower in patients assigned to natalizumab compared with placebo. 14 Other reported benefi ts from natalizumab therapy include a signifi cantly increased probability of maintaining disease-free status 17 and clinically signifi cant improvements on patient-reported quality-of-life measures. 18 Although there have been no head-to-head studies of natalizumab with interferon beta, glatiramer acetate, or fi ngolimod, there is a widespread view that treatment benefi ts of natalizumab exceed those of other diseasemodifying drugs. In clinical practice, patients with MS who experience breakthrough disease on standard disease-modifying drugs are routinely observed to achieve disease control after switching to natalizumab. Thus, based purely on effi cacy, patient-reported outcomes, and the convenience of once-monthly intravenous infusion, natalizumab represents an extremely attractive treatment option for patients with relapsing-remitting MS.
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Use discontinued in 2005
Natalizumab was approved for treatment of relapsing-remitting MS in November 2004, using the FDA accelerated review pathway. The approval was based on the fi rst-year results of the AFFIRM 14 and the Natalizumab plus Interferon Beta-1a for Relapsing Remitting Multiple Sclerosis (SENTINEL) 19 studies, both of which were completed in February 2005. In the 3 to 4 months between the drug's approval and completion of the AFFIRM and SENTINEL studies, approximately 7,000 patients with relapsingremitting MS received treatment with natalizumab. In February 2005, shortly after the release of the 2-year data, three cases of progressive multifocal leukoencephalopathy (PML) were identifi ed in natalizumab-treated patients (one with Crohn disease, the other two with MS). Clinical and research use of natalizumab was abruptly suspended that month, pending a comprehensive safety review.
A safety study evaluated 3,116 patients who had received natalizumab over a mean exposure of 17.9 monthly doses. 20 The study failed to identify any additional cases of PML and concluded that the risk of PML was approximately 1 in 1,000 patients. Abrupt discontinuation of natalizumab also allowed systematic assessment of disease behavior following treatment interruption. In 1,866 patients who had received natalizumab during clinical trials but who discontinued natalizumab after PML was recognized, MS relapses and gadolinium-enhancing lesions returned approximately to baseline levels within 4 to 7 months of natalizumab suspension. Reactivation of MS disease activity was observed even in patients who instituted one of the fi rst-line disease-modifying drugs as substitute therapy. 21 Based on the strong effi cacy data and the extensive safety review, an FDA advisory committee recommended reintroduction, and natalizumab was returned to the market in June 2006. Natalizumab may be administered only in accredited infusion centers that agree to a monthly reporting regimen designed to identify all cases of PML. In the United States, natalizumab is available to patients only through the Tysabri Outreach Unifi ed Commitment to Health (TOUCH) Prescribing Program, a restricted distribution program. Aggressive monitoring and reporting is also required in other regions of the world, so that ascertainment of PML associated with natalizumab is thought to be relatively complete.
Risk related to duration of therapy
As of June 30, 2011, some 88,100 patients had been dosed with natalizumab in the postmarketing setting. 22 The overall risk of PML in these patients was originally estimated to be 1 in 1,000 individuals taking the drug; the risk now is estimated to be 1.66 in 1,000 patients. Postmarketing surveillance has revealed differences in risk when duration of therapy is considered (Figure 1 ). 22 The most recent data indicate that, for those receiving between 1 and 24 infusions, the risk of PML is exceedingly low: 0.3 per 1,000 patients. For patients receiving between 25 and 36 infusions, the PML risk increases to approximately 1.5 per 1,000 patients. Although the number of cases receiving natalizumab for more than 36 infusions is more limited, the risk does not appear to increase further-the most recent estimated risk of PML for patients receiving 37 to 48 infusions is 0.9 per 1,000 patients. 22 The use of immunosuppressive drugs, including antimetabolites (eg, azathioprine), alkylating agents (eg, cyclophosphamide), or anthracenediones (eg, mitoxantrone) prior to natalizumab exposure appears to be an independent risk factor for natalizumab-associated PML, raising risk by approximately two-to fourfold.
Of the fi rst 35 cases of natalizumab-associated PML, 10 cases (29%) were fatal. Among surviving patients, the level of disability was found to be severe in 48%; moderate in 36%; and mild in 16%. 23 Improved survival was associated with younger age, less MS-related disability prior to PML, more localized disease on brain MRI at diagnosis, and shorter time from symptom onset to PML diagnosis. 23 As of August 4, 2011, there were 150 confi rmed cases of natalizumab-associated PML (58 in the United States, 85 in Europe, and 7 from the rest of the world); of these, 29 (19%) have died. 22 
  VARIATION IN PATIENT RISK TOLERANCE
The postmarketing surveillance of natalizumab clearly demonstrates that risk is associated with administration of the drug, but risk tolerance varies considerably among individuals with MS. Some patients elect to use natalizumab despite the risk of PML, even when they have relatively mild MS. Other patients decline use of natalizumab even when their MS is severe and has responded poorly to other disease-modifying drugs.
In most cases, based on my experience, patients accept the risk of natalizumab-associated PML if MS disease is their primary consideration. Another major factor is the patient's prior experiences with disease-modifying drugs; patients who have experienced breakthrough disease activity despite treatment with fi rst-line drugs commonly opt for natalizumab regardless of the risk of PML.
Interestingly, the treating neurologist's perception of MS severity and risk of PML may differ from the patient's perception. In a study of 69 natalizumab-treated MS patients and 66 neurologists, Heesen et al found that patients had a signifi cantly worse perception of their disease and were more willing to assume treatment risks and continue natalizumab therapy than their neurologists were. 24 About onehalf of the neurologists said that they would discontinue natalizumab at a risk level of 1 in 5,000 or lower, whereas only 17% of the patients would stop at this risk level. This fi nding has signifi cant implications for clinical practice and implies that the neurologist should discuss concerns about MS and risk of treatment with the patient in order to tailor the decision to the patient's concerns.
Interest in identifying biomarkers to aid in quantifying risk is ongoing. Chen et al found that subclinical reactivation of the JC virus (JCV) occurred frequently in 19 natalizumab-treated MS patients. 25 Another study of 24 natalizumab-treated MS patients found no JCV DNA in the blood, although JCV DNA was found in the urine in 25% of patients. 26 A large survey of blood and urine from natalizumab-treated MS patients found low sensitivity and specifi city for JCV DNA as a predictor for subsequent PML. 27 In this study of more than 1,000 natalizumab-treated patients, JCV DNA was detected in 0.3% of patients' plasma and in 26% of patients' urine, but PML did not develop in any patient who was JCVpositive. Among fi ve natalizumab-treated patients who developed PML, JCV DNA was detected in none before the advent of symptoms. The presence of JCV DNA in bodily fl uids is important for the diagnosis of PML, but it currently holds no predictive clinical value. At present, measuring JCV DNA in blood, cells, or urine as The incidence for each time period is calculated as the number of PML cases divided by the number of patients exposed to natalizumab (eg, for ≥ 24 infusions, the number of PML cases diagnosed with exposure of 24 infusions or more is divided by the total number of patients exposed to at least 24 infusions). (B) The incidence for each epoch is calculated as the number of PML cases divided by the number of patients exposed to natalizumab (eg, for 25 to 36 infusions, the number of PML cases diagnosed during this period is divided by the total number of patients ever exposed to at least 25 infusions and therefore having risk of developing PML during this time).
Source: Data on fi le. Biogen Idec; 2011.
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Stratifying risk by measuring JCV serology, however, does appear to be a useful strategy. Investigators using a two-step assay to detect and quantify JCV antibodies found 53.6% of MS patients to be seropositive, with a false-negative rate of 2.5%. Of most interest, all 17 natalizumab-associated PML patients who had available blood samples taken an average of 2 years before onset of PML tested positive for JCV antibodies. 28 Although studies are ongoing, classifi cation according to JCVantibody status may be helpful in advising patients. Patients who are JCV-antibody seronegative (about onehalf of patients) appear to be at extraordinarily low risk for PML. In these patients, use of natalizumab could be liberalized and continued as long as the JCV-antibody status remains negative. In patients who are seropositive for JCV antibodies, caution is recommended, particularly for patients who had prior immunosuppressive drug therapy and for patients who have received treatment for more than 24 months. Even in JCV-antibody-seropositive patients, use of natalizumab may be advisable depending on disease severity, available options, and the patient's risk tolerance. JCV-antibody testing is a rare example of a clinically useful biomarker that can guide specifi c treatment decisions in the fi eld of neurology.
   CURRENT PRACTICE: A PERSONAL
MANAGEMENT ALGORITHM Based on current evidence, the following opinion on the use of natalizumab for the treatment of MS is offered as a supplement to approved prescribing information. The neurologist must individualize the treatment decision for each patient and recognize that these general comments represent a personal opinion. Several factors affect decisions about the use of disease-modifying drugs in MS, and specifi cally use of natalizumab: How severe is the disease, and what is the prognosis for future disease progression from the neurologist's perspective? How concerned is the patient about current or future MS symptoms and disability? What is the patient's tolerance for medication side effects? For risk taking? Has there been prior immuno suppressive therapy? What is the JCV antibody status? What other options are available for disease management?
These issues require discussion among the neurologist, the patient, and the patient's family. The neurologist should provide input on disease status, an opinion about prognosis, and a description of appropriate options for disease management. Many patients also want a global recommendation (ie, "Tell me what you think I should do"). The neurologist must tailor that global recommendation to the patient's perceptions of his or her MS, its treatment, and preferences regarding treatment options.
My current, evolving view of the management of relapsing-remitting MS is outlined in Figure 2 . For treatment-naïve patients with active MS who are seronegative for JCV antibodies, I recommend that natalizumab be considered, with JCV serology repeated yearly (Figure 2A) . For patients who are JCV-antibodyseronegative and have breakthrough disease, I also recommend natalizumab with JCV serology repeated yearly. If the patient is treatment-naïve and seropositive, I recommend a fi rst-line drug or fi ngolimod. If the seropositive patient develops breakthrough disease, is risk tolerant, and has not been treated with prior immunosuppressive drugs, I advise switching to natalizumab for 1 to 2 years to determine response and then reassess.
For patients who are already receiving treatment with a fi rst-line drug and whose disease is well controlled, I make no changes in treatment until a breakthrough occurs, at which time I recommend switching to natalizumab with JCV antibody status assessed yearly ( Figure  2B ). If a patient has been taking natalizumab for more than 2 years and is seronegative, I advise continuing natalizumab ( Figure 2C ). If seropositive after 2 or more years of natalizumab therapy, I recommend switching to fi ngolimod and monitoring for disease reactivation.
  DISCUSSION
Dr. Calabrese: Have you perceived growing concern over PML among the MS patient population over the past 2 to 3 years? Dr. Rudick: I would say that it's pretty stable. Patients who are risk intolerant select out of natalizumab. Some patients would just as soon take their chances with MS rather than deal with additional risk. Since we talk about the risk of PML with patients prior to treatment, the patients who choose natalizumab are able to deal with the risk. The diffi cult cases are those patients who will be severely disabled before long but choose not to go on natalizumab because they're very risk averse. It gets even more complicated when the closest family member (parents or spouse) want their relative to use natalizumab but the patient is risk averse. This can become quite complicated-for example, I've seen situations where the patient is a minor, and one parent wants their child to use natalizumab but the other is risk-averse. Spouses often see risk differently, and this has led to interesting and diffi cult discussions. In the case of a child with MS, I listen to preferences from family members, but otherwise I empower the patient to drive the decision.
Dr. Major: Our data seem to suggest a higher percentage of individuals who are seropositive-about 56%. The issue, however, is a lack of a standard to defi ne seropositive and seronegative. I suggested that the natalizumab manufacturer collect a bank of samples and allocate them to laboratories with no vested interest for polymerase chain reaction (PCR) assays, from which consensus defi nitions of seropositive and seronegative could be developed.
Dr. Calabrese:
Why is there no confi rmatory immunoassay for this virus? We don't have false positives for hepatitis B or human immunodefi ciency virus. We still seem to be relying on older technologies.
Dr. Major:
To determine the level of antibody, an enzyme-linked immunosorbent assay is just fi ne. Dr. Major: Specifi city is quite good. Everybody now uses the same antigen, the polyoma capsid antigen, VP1, to detect productive viral infection, but there are no set standards for the cutpoints to classify as seropositive and seronegative. Certainly, there's high sensitivity with PCR to detect JCV DNA in cerebrospinal fl uid (CSF), because we're able to detect very low copy levels of JCV DNA in the CSF.
Dr. Simpson: I would like to see a quantitative measure of risk versus benefi t for all of the drugs used in MS, not just natalizumab. When you look at any clinical trial, you see a table of adverse events and you see effi cacy measures, but you don't see the two combined. This really is necessary to compare drug A with drug B. Instead, we end up making decisions based on risk tolerance and rather soft criteria. One could argue that we don't want to be so algorithmic that we take the art out of medicine, but the criteria we use to make decisions are quite soft. I wonder whether you have any suggestions on a more quantitative approach.
Dr. Rudick:
This is an important point, but a diffi cult problem. We have much more information about PML associated with natalizumab than we do about many seri- The natalizumab-PML situation is somewhat unique. PML is a dramatic, often fatal, disease that is virtually never observed spontaneously in MS, and the strict reporting requirements have resulted in near-complete ascertainment and more precise risk estimates. This situation doesn't apply to most adverse events associated with other therapies-even for some severe adverse events. But you are correct-focusing exclusively on the risk of PML seems somewhat simplistic because there are clear risks with other drugs, and these need to be factored into treatment decisions.
Dr. Molloy: Do you have good tools that predict how a patient with MS will do over time?
Dr. Fox: We have fair tools, not great tools.
We're diagnosing MS earlier, sometimes at the fi rst symptom. We're even beginning to recognize it in patients without symptoms who have MS observed as an incidental MRI fi nding. It is diffi cult at the earliest stage of MS to predict severity with any confi dence. The best predictor we have is the severity of the disease by MRI criteria. This can provide a general guide to treatment decisions, but it is an imprecise predictor.
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